Abstract
The adverse effects of screening are not commonly studied. False-positive tests lead to discomfort, costs, and risks from additional diagnostic and therapeutic procedures. False-negative tests lead to a sense of security and delays in seeking medical help when symptoms develop. Labeling an individual with a false-positive test, or with a true-positive test for which there is no evidence that intervention makes a difference, e.g., intervention on an 80-year-old asymptomatic woman with hypercholesterolemia, can have a markedly negative impact on the quality of life. Interpreting statistical abnormalities out of clinical context, e.g., lending importance to a multiphasic blood screen showing “high” alkaline phosphatase in a teenager, leads to unnecessary costs and anxiety. The cost of screening programs that may not have been shown to do more good than harm is already having an impact on the resources available to diagnose and treatment symptomatic persons. Premature implementation of unproved screening programs will continue to decrease physician and public confidence in prevention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frank JW. Occult-blood screening for colorectal carcinoma: the risks. Am J Prev Med. 1985;1(4):25–32.
Wright CJ. Breast cancer screening: a different look at the evidence. Surgery. 1986;100:594–8.
Tacker SB. Quality of controlled trials. The case of imaging ultrasound in obstetrics: a review. Br J Obstet Gynaecol. 1985;92:437–444.
Lockwood C, Benacerraf B, Krinsky A, et al. A sonographic screening method for Down syndrome. Am J Obstet Gynecol. 1987;157:803–8.
Sorenson JR, Levy HL, Mangione TW, Sepe SJ. Parental response to repeat testing of infants with “false-positive” results in a newborn screening program. Pediatrics. 1986;73L2m:183–7.
Fyro K, Bodegard G. Four year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism. Acta Paediatr Scand. 1987;76:107–14.
Frank JW. Occult-blood screening for colorectal carcinoma: the yield and the costs. Am J Prev Med. 1985;1(5).
Sienko DG, Osuch JR, Camburn JF. The need for quality assurance in mammography. N Engl J Med. 1989;320:14, 941 [letter].
Fox RC. Essays in medical sociology. New York: John Wiley and Sons, 1979.
Bergman AB, Stamm SJ. The morbidity of cardiac nondisease in schoolchildren. N Engl J Med. 1967;276:18,1008–13.
MacDonald LA, Sackett DL, Haynes RB, Taylor DW. Labelling in hypertension: a review of the behavioural and psychological consequences. J Chronic Dis. 1984;37:12,933–42.
Cadman D, Chambers LW, Walter SD, et al. Evaluation of public health preschool child developmental screening: the process and outcomes of a community program. Am J Public Health. 1987;77:1,45–51.
Hampton ML, Anderson J, Lavizzo BS, Bergman AB. Sickle cell nondisease. Am J Dis Child. 1974;128:58–61.
Quill TE, Lipkin Jr. M, Greenland P. The medicalization of normal variants: the case of mitral valve prolapse. J Gen Intern Med. 1987;3:267–76.
Detection and management of asymptomatic hypercholesterolemia: document of the Toronto Working Group on Cholesterol Policy, Ontario Ministry of Health and Ontario Medical Association, 1989.
Becker MH. The tyranny of health promotion. Public Health Rev. 1986;14:15–25.
Bergman AB. The menace of mass screening. Am J Public Health. 1977;67:(7)601–2.
Author information
Authors and Affiliations
Additional information
Received from the Department of Pediatrics, University of Ottawa, Ontario, Canada.
Rights and permissions
About this article
Cite this article
Feldman, W. How serious are the adverse effects of screening?. J Gen Intern Med 5 (Suppl 2), S50–S53 (1990). https://doi.org/10.1007/BF02600842
Issue Date:
DOI: https://doi.org/10.1007/BF02600842